Palm And Rice Bran Oil Study

Glucose Response Clinical Trial

— PARBO  

Official title:

Effects of Liquid Oil vs Oleogel Co-ingested With a Carbohydrate-rich Meal on Human Blood Triglycerides, Glucose, Insulin and Appetite.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02969057
• Other study ID #: 2016/00932
• Status: Completed
• Phase: N/A
• Start date: October 2016
• Est. completion date: October 2017

Study information

• Verified date: July 2018
• Source: Clinical Nutrition Research Centre, Singapore
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of the present study is to compare the effects of liquid or solid state of food on glycaemia, lipaemia and insulinaemia. 25 participants aged between 21 and 45 years will be recruited from the general public in Singapore. Fingerpricks and cannulation may cause minor discomfort and there may be some slight bruising around the site. Fingerpricks and cannulation will be done by an experienced research nurse or a trained research officer to minimize participant discomfort. If bruising does occur, it should disappear within one day and it should not affect participants' regular daily activity. Participants will be limited to a maximum of one test per week. In addition, blood collection will be carried out in a sterile designated area and thus the risk of infection will be very low. On rare occasions, participants may feel unwell during or after the testing session. We have several metabolic suites with beds for these individuals to rest on. The research nurse and research officers will monitor the individuals' condition and they will be provided with a ride home if required. All the study foods will be prepared in a hygienic manner in a purpose-built research kitchen maintained to the highest hygiene standards. The research staff has undergone basic training in food hygiene procedures. Hence, the risk of infective acute gastroenteritis will be minimal. Participants will be provided with some snacks at the end of each testing session. They will also be reimbursed to compensate for their time and costs associated with travel and parking at the completion of the study. In addition, participants will be provided with their blood glucose, blood pressure, and body composition results, with a brief interpretation of these at the conclusion of the study.

Description:

Design: This will be a randomised, crossover study with five sessions in total. 1.) Instant rice porridge with orange juice, 2.) Instant rice porridge with palm oil, with orange juice 3.) Instant rice porridge with palm oleogel, with orange juice 4.) Instant rice porridge with liquid rice bran oil, with orange juice 5.) Instant rice porridge with rice bran oleogel, with orange juice

Study population: Healthy Chinese males (BMI 18-25 kgm-2) with body weight >/=45 kg, aged 21-45 years with normal fasting blood glucose (<6.0 mM), will be recruited from the general public in Singapore. The exclusion criteria are people with major chronic disease such as heart disease, cancer or diabetes mellitus, glucose-6-phosphate dehydrogenase (G-6-PD) deficiency, glucose intolerance, intolerances or allergies to test products, as well as individuals who are taking insulin or drugs known to affect glucose metabolism. People with a major medical or surgical event requiring hospitalization within the preceding 3 months, individuals with the presence of disease or drugs which influence digestion and absorption of nutrients, people who are on any therapeutic diet/ drug therapy and smokers will be excluded.

Screening visit: During the screening session, participants will receive an informed consent form and given ample time to go through it and rectify any queries they have. If they decide to take part in the study, they will be asked to sign the informed consent form. They will then be asked to complete a screening questionnaire, baseline measurements including anthropometric measurements, blood pressure, and physical activity level will be collected from each participant in order to determine their eligibility. Body weight and body composition will be measured using bioelectrical impedance analysis. Height will be measured using a stadiometer in order to calculate participants' BMI. Blood pressure will also be measured. All measurements will be taken in duplicate. Participants will then be scheduled for the 5 subsequent test visits. The screening visit will take approximately 1 hour.

Screening questionnaire: The screening questionnaire will include contact information, demographic, general health details, and physical activity level. This information will be used to determine whether the participant is eligible for the study, as well as to check for any possible confounders that may influence the study outcomes. Physical activity level will be measured using a previously validated international physical activity questionnaire.

Meal composition: The test meal will consist of cooking oil (palm oil or rice bran oil in either liquid or gelled form made with ethylcellulose), orange juice and commercially available instant porridge.

Test visits: During the testing sessions, participants' glycaemic, insulinaemic, and lipaemic responses to the test meals will be measured. Participants' metabolic satiety for the test meals will also be assessed at regular intervals throughout the testing session. The test duration for each treatment is 6.5 hours and the testing sessions will take place at least 1 week apart. Subjects will be instructed to avoid strenuous physical activity for at least 3 days and avoid caffeine and alcohol consumption for at least 1 day prior to visiting the CNRC for their study trials. Participants will be asked to standardise their diets and to refrain from alcohol and exercise the day before their testing sessions. At the beginning of the testing session, a cannula will be inserted into participants' arms. One fasting blood sample will be collected by fingerprick and venous cannulation. A drop of blood will be collected into a HemoCue® cuvette (Helsingborg, Sweden) for blood glucose analysis. In addition, 5 milliliters of venous blood will be collected into Vacutainers® (Belton Dickinson Diagnostics) containing disodium EDTA for the analyses of plasma triglyceride, insulin and non-esterified fatty acids concentrations. Participants will then consume treatment meal within 10 minutes. Blood samples will be taken at baseline, 10, 20, 30, 45, 60, 90, 120, 150 and 180, 210, 240, 270, 300, 330 and 360 minutes. The amount of blood that will be collected at every time point will be approximately 5 mL. A maximum of 16 blood samples for will be collected by fingerprick and cannulation. A total of 400mL approximately of blood will be taken for the study. Glycaemic, insulinaemic, and lipaemic responses will be determined using the method described by Wolever and Jenkins. The area under the curve will be determined as the area of those increments above baseline only.

Participants will also be asked to rate their 'liking' for the test meal. Participants will rate their 'overall liking' for the test meal on a 100 mm VAS anchored with 'dislike extremely' (0 mm), 'neither like or dislike' (50 mm) and 'like extremely' (100 mm) immediately after they consume the test meal. Metabolic satiety: On the testing session days, participants will be asked to record their appetite ratings on a 100 mm visual analogue scale (VAS) immediately before they consume the test meal, then at every 30 minutes interval as peak changes are usually observed at 15-30 minutes after a test meal, based on previous studies.. The appetite-rating questionnaire will include questions on hunger, desire to eat, prospective consumption, fullness, and preoccupation with thoughts of food.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 18
• Est. completion date: October 2017
• Est. primary completion date: October 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 21 Years to 45 Years

Eligibility

Inclusion Criteria:

• Healthy Chinese male

• Age between 21 and 45 years

• BMI 18-25 kg/m2

• Body weight >/=45 kg

• Normal Blood Pressure (=140/90 mmHg)

• Normal Fasting Blood Glucose (<6.0 mM)

Exclusion Criteria:

• People who take part in sports at competitive/endurance levels•

• People with major chronic disease such as heart disease, cancer or diabetes mellitus

• People who are glucose-6-phosphate dehydrogenase (G-6-PD) deficiency

• People who have intolerances or allergies to test products

• Individuals who are taking insulin or drugs known to affect glucose metabolism and body fat distribution

• People with a major medical or surgical event requiring hospitalization within the preceding three months

• Individuals with the presence of disease or drugs which influence digestion and absorption of nutrients

• People who are on any therapeutic diet/ drug therapy

• Smokers

Related Conditions & MeSH terms

• Glucose Response

Intervention

Other:
• Breakfast with rice bran oil gel
25 grams of rice bran oil gel
• Breakfast with rice bran oil
25 grams of rice bran oil
• Breakfast with palm oil gel
25 grams of palm oil gel
• Breakfast with palm oil
25 grams of palm oil

Locations

Country	Name	City	State
Singapore	JeyaKumar Henry	Singapore

Sponsors (2)

Lead Sponsor	Collaborator
Clinical Nutrition Research Centre, Singapore	University of Guelph

Country where clinical trial is conducted

Singapore, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in postprandial blood glucose over 180 minutes period	Blood obtained through fingerprick, analysed using Hemocue analyser.	180 minutes
Primary	Change in postprandial serum triglyceride over 360 minutes period	Venous blood obtain through cannula, analysed using Cobas analyser. Venous plasma triglyceride will be assessed at 0, 10, 20, 30, 45, 60, 90, 120, 150 and 180, 210, 240, 270, 300, 330 and 360 minutes	360 minutes
Primary	Change in postprandial serum glucose over 360 minutes period	Venous blood obtain through cannula, analysed using Cobas analyser. Venous plasma triglyceride will be assessed at 0, 10, 20, 30, 45, 60, 90, 120, 150 and 180, 210, 240, 270, 300, 330 and 360 minutes	360 minutes
Secondary	Change in postprandial plasma insulin over 360 minutes period	Venous blood obtain through cannula, analysed using Cobas analyser. Venous plasma insulin will be assessed at 0, 10, 20, 30, 45, 60, 90, 120, 150 and 180, 210, 240, 270, 300, 330 and 360 minutes	360 minutes
Secondary	Change in postprandial appetite over 360 minutes period	Appetite ratings will be assessed at 10, 20, 30, 45, 60, 90, 120, 150 and 180, 210, 240, 270, 300, 330 and 360 minutes	360 minutes